Pregabalin Pfizer

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

pregabalin

Available from:

Upjohn EESV

ATC code:

N03AX16

INN (International Name):

pregabalin

Therapeutic group:

Antiepileptics,

Therapeutic area:

Anxiety Disorders; Epilepsy

Therapeutic indications:

Nevropatske painPregabalin Pfizer je primerna za zdravljenje periferne in centralne nevropatske bolečine pri odraslih. EpilepsyPregabalin Pfizer je označen kot adjunctive terapija pri odraslih z delni epileptični napadi z ali brez sekundarne posplošitev. Splošne Anksioznosti DisorderPregabalin Pfizer je primerna za zdravljenje Splošne Anksiozne Motnje (GAD) pri odraslih.

Product summary:

Revision: 29

Authorization status:

Pooblaščeni

Authorization date:

2014-04-10

Patient Information leaflet

                                25
9.
POSEBNA NAVODILA ZA SHRANJEVANJE
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Upjohn EESV
Rivium Westlaan 142
2909 LD Capelle aan den IJssel
Nizozemska
12.
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET
EU/1/14/916/001-005
EU/1/14/916/006
EU/1/14/916/007
13.
ŠTEVILKA SERIJE
Lot
14.
NAČIN IZDAJANJA ZDRAVILA
15.
NAVODILA ZA UPORABO
16.
PODATKI V BRAILLOVI PISAVI
Pregabalin Pfizer 25 mg
17.
EDINSTVENA OZNAKA – DVODIMENZIONALNA ČRTNA KODA
Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.
18.
EDINSTVENA OZNAKA – V BERLJIVI OBLIKI
PC
SN
NN
26
PODATKI NA ZUNANJI OVOJNINI
ŠKATLA S PLASTENKO ZA 25 MG TRDE KAPSULE – PAKIRANJE PO 200
1.
IME ZDRAVILA
Pregabalin Pfizer 25 mg trde kapsule
pregabalin
2.
NAVEDBA ENE ALI VEČ UČINKOVIN
Ena trda kapsula vsebuje 25 mg pregabalina.
3.
SEZNAM POMOŽNIH SNOVI
Vsebuje laktozo monohidrat. Pred uporabo preberite priloženo
navodilo!
4.
FARMACEVTSKA OBLIKA IN VSEBINA
200 trdih kapsul
5.
POSTOPEK IN POT(I) UPORABE ZDRAVILA
za peroralno uporabo
6.
POSEBNO OPOZORILO O SHRANJEVANJU ZDRAVILA ZUNAJ DOSEGA IN
POGLEDA OTROK
Zdravilo shranjujte nedosegljivo otrokom!
7.
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA
8.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP
9.
POSEBNA NAVODILA ZA SHRANJEVANJE
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
27
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Upjohn EESV
Rivium Westlaan 142
2909 LD Capelle aan den IJssel
Nizozemska
12.
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET
EU/1/14/916/044
13.
ŠTEVILKA SERIJE
Lot
14.
NAČIN IZDAJANJA ZDRAVILA
15.
NAVODILA ZA UPORABO
16.
PODATKI V BRAILLOVI PISAVI
Pregabalin Pfizer 25 mg
17.
EDINSTVENA OZNAKA – DVODIMENZIONALNA ČRTNA KODA
Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.
18.
EDINSTVENA OZNAKA – V BERLJIVI OBLIKI
PC
SN
NN
28
PODATKI, KI MORAJO BITI NAJM
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
2
1.
IME ZDRAVILA
Pregabalin Pfizer 25 mg trde kapsule
Pregabalin Pfizer 50 mg trde kapsule
Pregabalin Pfizer 75 mg trde kapsule
Pregabalin Pfizer 100 mg trde kapsule
Pregabalin Pfizer 150 mg trde kapsule
Pregabalin Pfizer 200 mg trde kapsule
Pregabalin Pfizer 225 mg trde kapsule
Pregabalin Pfizer 300 mg trde kapsule
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
Pregabalin Pfizer 25 mg trde kapsule
Ena trda kapsula vsebuje 25 mg pregabalina.
_ _
Pregabalin Pfizer 50 mg trde kapsule
Ena trda kapsula vsebuje 50 mg pregabalina.
_ _
_ _
Pregabalin Pfizer 75 mg trde kapsule
Ena trda kapsula vsebuje 75 mg pregabalina.
_ _
Pregabalin Pfizer 100 mg trde kapsule
Ena trda kapsula vsebuje 100 mg pregabalina.
_ _
Pregabalin Pfizer 150 mg trde kapsule
Ena trda kapsula vsebuje 150 mg pregabalina.
_ _
Pregabalin Pfizer 200 mg trde kapsule
Ena trda kapsula vsebuje 200 mg pregabalina.
_ _
Pregabalin Pfizer 225 mg trde kapsule
Ena trda kapsula vsebuje 225 mg pregabalina.
_ _
Pregabalin Pfizer 300 mg trde kapsule
Ena trda kapsula vsebuje 300 mg pregabalina.
_ _
Pomožna snov z znanim učinkom:
Pregabalin Pfizer 25 mg trde kapsule
Ena trda kapsula vsebuje tudi 35 mg laktoze monohidrata.
Pregabalin Pfizer 50 mg trde kapsule
Ena trda kapsula vsebuje tudi 70 mg laktoze monohidrata.
Pregabalin Pfizer 75 mg trde kapsule
Ena trda kapsula vsebuje tudi 8,25 mg laktoze monohidrata.
Pregabalin Pfizer 100 mg trde kapsule
Ena trda kapsula vsebuje tudi 11 mg laktoze monohidrata.
Pregabalin Pfizer 150 mg trde kapsule
Ena trda kapsula vsebuje tudi 16,50 mg laktoze monohidrata.
Pregabalin Pfizer 200 mg trde kapsule
Ena trda kapsula vsebuje tudi 22 mg laktoze monohidrata.
3
Pregabalin Pfizer 225 mg trde kapsule
Ena trda kapsula vsebuje tudi 24,75 mg laktoze monohidrata.
Pregabalin Pfizer 300 mg trde kapsule
Ena trda kapsula vsebuje tudi 33 mg laktoze monohidrata.
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
trde kapsule
Pregabalin Pfizer 25 mg trde kapsule
Bela kapsula, ki im
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 12-01-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 12-01-2024
Public Assessment Report Public Assessment Report Bulgarian 07-05-2014
Patient Information leaflet Patient Information leaflet Spanish 12-01-2024
Public Assessment Report Public Assessment Report Spanish 07-05-2014
Patient Information leaflet Patient Information leaflet Czech 12-01-2024
Public Assessment Report Public Assessment Report Czech 07-05-2014
Patient Information leaflet Patient Information leaflet Danish 12-01-2024
Public Assessment Report Public Assessment Report Danish 07-05-2014
Patient Information leaflet Patient Information leaflet German 12-01-2024
Public Assessment Report Public Assessment Report German 07-05-2014
Patient Information leaflet Patient Information leaflet Estonian 12-01-2024
Public Assessment Report Public Assessment Report Estonian 07-05-2014
Patient Information leaflet Patient Information leaflet Greek 12-01-2024
Public Assessment Report Public Assessment Report Greek 07-05-2014
Patient Information leaflet Patient Information leaflet English 12-01-2024
Public Assessment Report Public Assessment Report English 07-05-2014
Patient Information leaflet Patient Information leaflet French 12-01-2024
Public Assessment Report Public Assessment Report French 07-05-2014
Patient Information leaflet Patient Information leaflet Italian 12-01-2024
Public Assessment Report Public Assessment Report Italian 07-05-2014
Patient Information leaflet Patient Information leaflet Latvian 12-01-2024
Public Assessment Report Public Assessment Report Latvian 07-05-2014
Patient Information leaflet Patient Information leaflet Lithuanian 12-01-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 12-01-2024
Public Assessment Report Public Assessment Report Lithuanian 07-05-2014
Patient Information leaflet Patient Information leaflet Hungarian 12-01-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 12-01-2024
Public Assessment Report Public Assessment Report Hungarian 07-05-2014
Patient Information leaflet Patient Information leaflet Maltese 12-01-2024
Public Assessment Report Public Assessment Report Maltese 07-05-2014
Patient Information leaflet Patient Information leaflet Dutch 12-01-2024
Public Assessment Report Public Assessment Report Dutch 07-05-2014
Patient Information leaflet Patient Information leaflet Polish 12-01-2024
Public Assessment Report Public Assessment Report Polish 07-05-2014
Patient Information leaflet Patient Information leaflet Portuguese 12-01-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 12-01-2024
Public Assessment Report Public Assessment Report Portuguese 07-05-2014
Patient Information leaflet Patient Information leaflet Romanian 12-01-2024
Public Assessment Report Public Assessment Report Romanian 07-05-2014
Patient Information leaflet Patient Information leaflet Slovak 12-01-2024
Public Assessment Report Public Assessment Report Slovak 07-05-2014
Patient Information leaflet Patient Information leaflet Finnish 12-01-2024
Public Assessment Report Public Assessment Report Finnish 07-05-2014
Patient Information leaflet Patient Information leaflet Swedish 12-01-2024
Public Assessment Report Public Assessment Report Swedish 07-05-2014
Patient Information leaflet Patient Information leaflet Norwegian 12-01-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 12-01-2024
Patient Information leaflet Patient Information leaflet Icelandic 12-01-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 12-01-2024
Patient Information leaflet Patient Information leaflet Croatian 12-01-2024
Public Assessment Report Public Assessment Report Croatian 07-05-2014

Search alerts related to this product